GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Forward Dividend Yield %
中文

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Forward Dividend Yield %

: 2.26% (As of Today)
View and export this data going back to 2010. Start your Free Trial

As of today (2024-04-23), the Forward Annual Dividend Yield of Santen Pharmaceutical Co is 2.26%.

As of today (2024-04-23), the Trailing Annual Dividend Yield of Santen Pharmaceutical Co is 2.26%.

SNPHY's Forward Dividend Yield % is ranked better than
59.68% of 496 companies
in the Drug Manufacturers industry
Industry Median: 1.87 vs SNPHY: 2.26

Santen Pharmaceutical Co's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

During the past 3 years, the average Dividends Per Share Growth Rate was 5.80% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 5.00% per year. During the past 10 years, the average Dividends Per Share Growth Rate was 4.80% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Santen Pharmaceutical Co was 17.00% per year. The lowest was 1.30% per year. And the median was 6.50% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co Forward Dividend Yield % Distribution

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Forward Dividend Yield % falls into.



Santen Pharmaceutical Co Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Santen Pharmaceutical Co Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
USD 0.1082023-09-282023-09-292023-12-15Cash Dividendsemi-annuallyUSD:USD 1.000000

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Santen Pharmaceutical Co's Forward Annual Dividend Yield (%) for Today is calculated as

Forward Annual Dividend Yield=Forward Full Year Dividend/Current Share Price
=0.216/9.65
=2.24 %

Current Share Price is $9.65.
Santen Pharmaceutical Co's Dividends per Share for the forward twelve months is calculated as $0.108 * 2 = $0.216.

Santen Pharmaceutical Co's Trailing Annual Dividend Yield (%) for Today is calculated as

Trailing Annual Dividend Yield=Most Recent Full Year Dividend/Current Share Price
=0.108/9.65
=1.12 %

Current Share Price is $9.65.
Santen Pharmaceutical Co's Dividends per Share for the trailing twelve months (TTM) ended in Today is $0.108.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santen Pharmaceutical Co  (OTCPK:SNPHY) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Santen Pharmaceutical Co Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020